Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 73 |
| Active Pipeline (Recruiting Now) | 55 (31) |
| Completed vs Stopped Early | 10 / 7 (9.6%) |
| Median Closed Actual Enrollment | 80 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Centre Antoine-Lacassagne | Nice | 29 |
| Gustave Roussy | Villejuif, Île-de-France Region | 25 |
| Centre Léon Bérard | Lyon | 25 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07106632 | Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests | Phase III | RECRUITING |
| NCT06680596 | Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy | Phase II | RECRUITING |
| NCT07237256 | Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib | Phase III | RECRUITING |
| NCT06078384 | Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC | Phase II | RECRUITING |
| NCT05973864 | Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery | Phase II | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the UNICANCER Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.